Cited by 796Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.

New insights into the pharmacodynamic and pharmacokinetic properties of statins

Corsini, Alberto, Bellosta, Stefano, Baetta, Roberta, Fumagalli, Remo, Paoletti, Rodolfo, Bernini, Franco·1999·Pharmacology & Therapeutics

DOI 10.1016/s0163-7258(99)00045-5

Open this paper in CoChat — free account

Abstract

The beneficial effects of statins are assumed to result from their ability to reduce cholesterol biosynthesis. However, because mevalonic acid is the precursor not only of cholesterol, but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase may result in pleiotropic effects. It has been shown that several statins decrease smooth muscle cell migration and proliferation and that sera from fluvastatin-treated patients interfere with its proliferation. Cholesterol accumulation in macrophages can be inhibited by different statins, while both fluvastatin and simvastatin inhibit secretion of metalloproteinases by human monocyte-derived macrophages. The antiatherosclerotic effects of statins may be achieved by modifying hypercholesterolemia and the arterial wall environment as well. Although statins rarely have severe adverse effects, interactions with other drugs deserve attention. Simvastatin, lovastatin, cerivastatin, and atorvastatin are biotransformed in the liver primarily by cytochrome P450-3A4, and are susceptible to drug interactions when co-administered with potential inhibitors of this enzyme. Indeed, pharmacokinetic interactions (e.g., increased bioavailability), myositis, and rhabdomyolysis have been reported following concurrent use of simvastatin or lovastatin and cyclosporine A, mibefradil, or nefazodone. In contrast, fluvastatin (mainly metabolized by cytochrome P450-2C9) and pravastatin (eliminated by other metabolic routes) are less subject to this interaction. Nevertheless, a 5- to 23-fold increase in pravastatin bioavailability has been reported in the presence of cyclosporine A. In summary, statins may have direct effects on the arterial wall, which may contribute to their antiatherosclerotic actions. Furthermore, some statins may have lower adverse drug interaction potential than others, which is an important determinant of safety during long-term therapy.

Integrity signals

Registry

Crossref · 10.1016/s0163-7258(99)00045-5

Cites

187 of 187 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 9,216
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Coronary Plaque Disruption
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 2,018

Show all 186 references

Research works printed but not linked: 8

Fischer, 1999, The HMG-CoA reductase inhibitor fluvastatin, Drug Metab Dispos, 27, 410
Henwood, 1995, Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia, Drugs, 31, 9
Hoffman, 1992, The interaction of lovastatin and warfarin, Conn Med, 56, 107
Mai, 1997, Clinical pharmacokinetics of a new HMG-CoA reductase inhibitor in renal transplant patients treated with cyclosporin A (CSA), Eur J Clin Pharmacol, 52, A137
Raiteri, 1997, Pharmacological control of the mevalonate pathway, J Pharmacol Exp Ther, 281, 1144
1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, Lancet, 344, 1383
Smith, 1991, HMG-CoA reductase inhibitor-induced myopathy in the rat, J Pharmacol Exp Ther, 257, 1225
Soma, 1995, In vitro and in vivo enhanced anti-tumor activity of carmustine (BCNU) by simvastatin, a hypocholesterolemic drug, Cancer Res, 55, 597

Sorted by citations

Items 401–500 of 794

Pharmacologic Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage
Smetana, K. S., Buschur, P. L., Owusu‐Guha, J., & May, C. C. (2020) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000299 · Cited by 21
Simvastatin Inhibits Glucose‐Stimulated Vascular Smooth Muscle Cell Migration Involving Increased Expression of RhoB and a Block of Ras/Akt Signal
Chan, K., Wu, C., Huang, C., Lan, K.-P., Chang, W. C., & Wang, C. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00226.x · Cited by 21
Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS).
Kaul, U., Varma, J., Kahali, D., Hiremath, M. S., Dani, S., Dalal, J. J., Ramchandran, P., Rane, R. C., Barkate, H. V., & Jindal, C. (2013) · PubMed · Cited by 21
The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP‐receptor
Lawler, O. A., Miggin, S. M., & Kinsella, B. T. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704033 · Cited by 21
Statins and inflammatory markers
Case, C. C., & Ballantyne, C. M. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0061-z · Cited by 21
Basic Science Review Section: Statin Therapy—Part II: Clinical Considerations for Cardiovascular Disease
Sadowitz, B. D., Seymour, K. A., Costanza, M. J., & Gahtan, V. (2010) · Vascular and Endovascular Surgery · doi:10.1177/1538574410363833 · Cited by 19
A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis
Collongues, N., Becker, G., Jolivel, V., Ayme‐Dietrich, E., Seze, J. D., Binamé, F., Patte‐Mensah, C., Monassier, L., & Mensah‐Nyagan, A. G. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00363-7 · Cited by 22
The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model
Stępień, K. M., Tomaszewski, M., Łuszczki, J. J., & Czuczwar, S. J. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.10.030 · Cited by 20
Statins and Selective Inhibition of Rho Kinase Protect Small Conductance Calcium-Activated Potassium Channel Function (KCa2.3) in Cerebral Arteries
McNeish, A. J., Jiménez‐Altayó, F., Cottrell, G. S., & Garland, C. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046735 · Cited by 20
Simvastatin interferes with process outgrowth and branching of oligodendrocytes
Smolders, I., Smets, I., Maier, O., vandeVen, M., Steels, P., & Ameloot, M. M. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22490 · Cited by 20
Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis
Reilly, J. E., Neighbors, J. D., Tong, H., Henry, M. D., & Hohl, R. J. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9727-0 · Cited by 20
Simvastatin inhibits neutrophil degranulation induced by anti-neutrophil cytoplasm auto-antibodies and N-formyl-methionine-leucine-phenylalanine (fMLP) peptide
Al‐Ani, B. (2013) · Saudi Medical Journal · doi:10.15537/1658-3175.5752 · Cited by 20
Safety and efficacy of early aggressive versus cholesterol-driven lipid-lowering strategies in heart transplantation: A pilot, randomized, intravascular ultrasound study
Potena, L., Grigioni, F., Ortolani, P., Magnani, G., Fabbri, F., Masetti, M., Coccolo, F., Fallani, F., Russo, A., Ionico, T., et al. (2011) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2011.07.002 · Cited by 19
Statins, bugs and prophylaxis: intriguing possibilities.
Terblanche, M., Smith, T. S., & Adhikari, N. K. J. (2006) · Critical Care · doi:10.1186/cc5056 · Cited by 19
Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Marzban, H., Kong, J., Mehr, S. E., Vriend, J. P., Li, J., Guan, T., Chung, S., Mirzaei, N., Marzban, A., Shojaei, S., et al. (2016) · Current Molecular Pharmacology · doi:10.2174/1874467209666160112125446 · Cited by 20
Cerivastatin‐Induced Rhabdomyolysis: 11 Case Reports
Ravnan, S. L., Locke, C., Yee, W. P., & Haase, K. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.7.533.33674 · Cited by 20
Facts and ideas on statins with respect to their lipophilicity: a focus on skeletal muscle cells and bone besides known cardioprotection
Švec, A., & Adameová, A. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04621-y · Cited by 20
Anti-inflammatory and hypolipemic effects in vitro of simvastatin comparing to epicatechin in patients with type-2 hypercholesterolemia
Pietryga, I. F., Koter−Michalak, M., Broncel, M., Duchnowicz, P., & Chojnowska-Jezierska, J. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.11.027 · Cited by 19
Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells
Werner, M., Atil, B., Berger–Sieczkowski, E., Chiba, P., & HOHENEGGER, M. (2013) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-013-0859-y · Cited by 19
Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients
van der Weide, K., de Jonge-Peeters, S. D. P. W. M., Huls, G. A., Fehrmann, R. S. N., Schuringa, J. J., Kuipers, F., de Vries, E. G. E., & Vellenga, E. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.11.008 · Cited by 19
POSSIBLE REGULATION OF LDL-RECEPTOR BY NARINGENIN IN HEPG2 HEPATOMA CELL LINE
Bawazeer, N. A., Choudary, H., Zamzami, M. A., Abdulaal, W. H., Zeyadi, M., Albukhari, A., Middleton, B., & Moselhy, S. S. (2016) · African Journal of Traditional Complementary and Alternative Medicines · doi:10.21010/ajtcam.v14i1.30 · Cited by 19
Treatment of the Metabolic Disturbances Caused by Antipsychotic Drugs
Baptista, T., Kin, N. M. K. N. Y., & Beaulieu, S. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443010-00001 · Cited by 19
Emphasizing Statin Safety in the Hospitalized Patient: A Review
Leung, A., Schaefer, É., Tempelhof, M. W., & Stone, N. J. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.02.022 · Cited by 18
Lipophilic Statins Eliminate Senescent Endothelial Cells by inducing Anoikis-Related Cell Death
Beláková, B., Wedige, N., Awad, E. M., Heß, S., Oszwald, A., Fellner, M., Khan, S. Y., Resch, U., Lipovac, M., Šmejkal, K., et al. (2023) · Cells · doi:10.3390/cells12242836 · Cited by 18
Pharmacologic Management of Isolated Low High-Density Lipoprotein Syndrome
Bermúdez, V., Cano, R., Cano, C., Bermúdez, F., Arráiz, N., Acosta, L., Finol, F., Pabón, M. R., Amell, A., Reyna, N., et al. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318169bc0b · Cited by 17
Development and Characterization of Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) of Atorvastatin Calcium
Kumar, M. S., Pashikanti, S., & Murthy, K. V. R. (2012) · Current Drug Delivery · doi:10.2174/156720112800234594 · Cited by 18
Pleiotropic Effects of Statins
Pella, D., Rybár, R., & Mechírová, V. (2005) · Zhōnghuá mínguó xīnzàngxué huì zázhì · Cited by 18
Cognitive Function Assessment in Patients on Moderate- or High-Intensity Statin Therapy
Roy, S., Hyman, D., Ayyala, S., Bakhshi, A., Kim, S. H., Anoruo, N., Weinstock, J. L., Balogun, A., D’Souza, M., Filatova, N., et al. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4144 · Cited by 18
Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
Márk, L., Márki‐Zay, J., Fodor, L., Hajdara, I., Paragh, G., & Katona, A. (2006) · PubMed · Cited by 18
Avoiding statin myopathy: understanding key drug interactions
Harper, C. H., & Jacobson, T. A. (2011) · Clinical Lipidology · doi:10.2217/clp.11.57 · Cited by 18
Lovastatin, but not pravastatin, limits in vitro infection due to Coxiella burnetii
Botelho-Nevers, É., Espinosa, L., Raoult, D., & Rolain, J. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn282 · Cited by 18
Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition
Hu, M., Mak, V. W. L., & Tomlinson, B. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01184.x · Cited by 18
Cholesterol-Lowering Drugs And Alzheimer’S Disease
Eckert, G. P., Müller, W. E., & Wood, G. W. (2007) · Future Lipidology · doi:10.2217/17460875.2.4.423 · Cited by 18
Antihypertensive therapy: special focus on drug interactions
Maas, R., & Böger, R. H. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.6.549 · Cited by 18
Lovastatin Extended Release
Curran, M. P., & Goa, K. L. (2003) · Drugs · doi:10.2165/00003495-200363070-00007 · Cited by 18
Mecanismos de rabdomiólise com as estatinas
Magalhães, M. E. C. (2005) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2005002400011 · Cited by 17
Simvastatin decreases hepatic ischaemia/reperfusion-induced liver and lung injury in rats.
Dibazar, F., Hajipour, B., Hosseinian, M. M., Hemmati, M., & Ghandiha, A. (2008) · PubMed · Cited by 17
Investigation of Solid Dispersion of Atorvastatin Calcium in Polyethylene Glycol 6000 and Polyvinylpyrrolidone
Hu, L., Gu, D., Hu, Q., Shi, Y., & Gao, N. (2014) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v13i6.2 · Cited by 17
Pediatric Statin Administration: Navigating a Frontier with Limited Data
Wagner, J. B., & Abdel‐Rahman, S. M. (2016) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-21.5.380 · Cited by 17
Role of drugs and devices in patients at risk of sudden cardiac death
Boriani, G., Diemberger, I., Valzania, C., Biffi, M., Martignani, C., Raschi, E., Mantovani, V., Ziacchi, M., Bertini, M., Ponti, F. D., et al. (2010) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00853.x · Cited by 17
Prostacyclin receptors: Transcriptional regulation and novel signalling mechanisms
Reid, H. M., & Kinsella, B. T. (2015) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2015.04.008 · Cited by 21
HMG-CoA Reductase Inhibitor Pharmacogenomics: Overview and Implications for Practice
Zineh, I. (2005) · Future Cardiology · doi:10.1517/14796678.1.2.191 · Cited by 17
Statins limit Rickettsia conorii infection in cells
Botelho-Nevers, É., Rolain, J., Espinosa, L., & Raoult, D. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.04.027 · Cited by 17
Optimization of Hypolipidemic and Antiplatelet Treatment in the Diabetic Patient with Renal Disease
Trovati, M., & Cavalot, F. L. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000093238.09114.40 · Cited by 17
Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable?
Tomlinson, B., & Lan, I. W. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00691-x · Cited by 17
Simvastatin and non‐segmental vitiligo: A new potential treatment option?
Shaker, E. S. E., Allam, S. H., Mabrouk, M. M., El-Gharbawy, N. M., & Salaam, S. F. A. (2022) · Dermatologic Therapy · doi:10.1111/dth.15969 · Cited by 16
Do statins really cause diabetes?
Rahal, A. J., El‐Mallah, A., Poushuju, R. J., & Itani, R. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.10.16078 · Cited by 16
Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations
Nagy, Á., Sipeky, C., Szalai, R., Melegh, B., Mátyás, P., Ganczer, A., Tóth, K., & Melegh, B. (2015) · BMC Genetics · doi:10.1186/s12863-015-0262-4 · Cited by 16
Acute Modulation of Vasoconstrictor Responses by Pravastatin in Small Vessels
Ghaffari, N., Ball, C. J., Kennedy, J. A., Stafford, I., & Beltrame, J. F. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-0954 · Cited by 16
Evaluation of In Vitro Equivalence for Tablets Containing the Poorly WaterSoluble Compound Atorvastatin
Popy, F. A., Dewan, I., Parvin, M. N., & Islam, S. M. A. (2012) · Dissolution Technologies · doi:10.14227/dt190412p30 · Cited by 16
Potential therapeutic roles of 10-dehydrogingerdione and/or pentoxifylline against calcium deposition in aortic tissues of high dietary cholesterol-fed rabbits
Elseweidy, M. M., Mohamed, H. E., Elrashidy, R. A., Atteia, H. H., Elnagar, G. M., & Ali, A. A. (2018) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-018-3438-1 · Cited by 16
Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers
Bucher, M., Mair, G., & Kees, F. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0385-6 · Cited by 16
Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART
Negredo, E., Puigdomènech, I., Marfil, S., Puig, J., Pérez‐Álvarez, N., Ruiz, L., Rey‐Joly, C., Clotet, B., & Blanco, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm470 · Cited by 16
Pitavastatin: a distinctive lipid-lowering drug
Ose, L. (2010) · Clinical Lipidology · doi:10.2217/clp.10.28 · Cited by 16
Expedition of in vitro dissolution and in vivo pharmacokinetic profiling of sulfur nanoparticles based antimicrobials
Choudhury, S. R., Basu, A., Nag, T., Sengupta, K., Bhowmik, M., & Goswami, A. (2013) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2013.06.014 · Cited by 15
Management of intracerebral hemorrhage – use of statins
Kiser, T. H., Matre, E. T. V., & Sherman, D. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s75399 · Cited by 15
Spatial structure of atorvastatin and its complex with model membrane in solution studied by NMR and theoretical calculations
Galiullina, L. F., Musabirova, G., Анварович, Л. И., Aganov, A. V., & Klochkov, V. V. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.04.012 · Cited by 16
Leptin activates Akt in oesophageal cancer cells via multiple atorvastatin-sensitive small GTPases
Beales, I., & Ogunwobi, O. O. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04067-8 · Cited by 15
Statins and hearing
Whitlon, D. S. (2022) · Hearing Research · doi:10.1016/j.heares.2022.108453 · Cited by 15
Effect of Atorvastatin Treatment on Isoproterenol-Induced Myocardial Infarction in Rats
Trivedi, C. J., Balaraman, R., Majithiya, J. B., & Bothara, S. B. (2006) · Pharmacology · doi:10.1159/000092308 · Cited by 15
Atorvastatin Enhances Bone Density in Ovariectomized Rats Given 17β-Estradiol or Human Parathyroid Hormone(1-34)
Kawane, T., Terashima, S., Kurahashi, I., Yanagawa, T., Yoshida, H., & Horiuchi, N. (2004) · Endocrine · doi:10.1385/endo:24:2:121 · Cited by 15
Statins and breast cancer in postmenopausal women without hormone therapy.
Eaton, M., Eklof, J., Beal, J. R., & Sahmoun, A. E. (2009) · PubMed · Cited by 15
Pharmacokinetics of Fluvastatin in Subjects with Renal Impairment and Nephrotic Syndrome
Appel‐Dingemanse, S., Smith, T., & Merz, M. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011346 · Cited by 15
Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era
Jacobson, T. A. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.3.269 · Cited by 15
Effect of the statin atorvastatin on intracellular signalling by the prostacyclin receptor in vitro and in vivo
O'Meara, S. J., & Kinsella, B. T. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705947 · Cited by 15
Synthesis, activity, metabolic stability, and pharmacokinetics of glucocorticoid receptor modulator–statin hybrids
Link, J. T., Sorensen, B. K., Lai, C., Wang, J., Fung, S., Deng, D., Emery, M. G., Carroll, S., Grynfarb, M., Goos‐Nilsson, A., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.06.021 · Cited by 15
FLUVASTATIN IN COMBINATION WITH RAD SIGNIFICANTLY REDUCES GRAFT VASCULAR DISEASE IN RAT CARDIAC ALLOGRAFTS1
Gregory, C. R., Katznelson, S., Griffey, S. M., Kyles, A. E., & Berryman, E. R. (2001) · Transplantation · doi:10.1097/00007890-200109270-00002 · Cited by 15
Statin therapy influences endothelial cell morphology and F-actin cytoskeleton structure when exposed to static and laminar shear stress conditions
Dick, M., Jonak, P., & Leask, R. L. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.03.002 · Cited by 14
Co-amorphization of atorvastatin by lisinopril as a co-former for solubility improvement
Li, W., Song, J., Li, J., Li, M., Tian, B., He, Z., Liu, X., & Fu, Q. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120971 · Cited by 14
Efficacy of alternate day dosing of atorvastatin
Aghasadeghi, K., & Zare, D. (2007) · Open Medicine · doi:10.2478/s11536-007-0063-x · Cited by 14
Therapy to reduce risk of coronary heart disease
Rader, D. J. (2003) · Clinical Cardiology · doi:10.1002/clc.4960260103 · Cited by 14
Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1
Ferri, N., Marchianò, S., Lupo, M. G., Trenti, A., Biondo, G., Castaldello, P., & Corsini, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.021 · Cited by 14
Self-citation
Statins: Pharmacokinetics, Pharmacodynamics and Cost-Effectiveness Analysis
Ricci, G., Ciccone, M. M., Giordano, P., & Cortese, F. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180706144824 · Cited by 14
Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin
Schindler, C., Thoms, M., Matschke, K. E., Tugtekin, S. M., & Kirch, W. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.017 · Cited by 14
Cerivastatin-induced apoptosis of human aortic smooth muscle cells through partial inhibition of basal activation of extracellular signal-regulated kinases
Takata, R., Fukasawa, S., Hara, T., Nakajima, H., Yamashina, A., Yanase, N., & Mizuguchi, J. (2004) · Cardiovascular Pathology · doi:10.1016/s1054-8807(03)00104-2 · Cited by 14
Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study
Panichi, V., Manca-Rizza, G., Paoletti, S., Taccola, D., Consani, C., Sbragia, G., Mantuano, E., Marchetti, V., Carpi, A., & Barsotti, G. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.04.004 · Cited by 14
Statins as a New Therapeutic Perspective in Myocarditis and Postmyocarditis Dilated Cardiomyopathy
Lazzerini, P. E., Capecchi, P. L., & Pasini, F. L. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6475-8 · Cited by 14
Xenosensors CAR and PXR at Work: Impact on Statin Metabolism
Marino, M., di Masi, A., Trezza, V., Pallottini, V., Polticelli, F., & Ascenzi, P. (2011) · Current Drug Metabolism · doi:10.2174/138920011795101859 · Cited by 13
The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study
Nagayama, D., Saiki, A., & Shirai, K. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s306540 · Cited by 13
The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study
Giorgi, R. D., Martens, M., Pesci, N. R., Cowen, P. J., & Harmer, C. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211060307 · Cited by 13
Photophysical characterization of atorvastatin (Lipitor®) ortho-hydroxy metabolite: role of hydroxyl group on the drug photochemistry
Alarcon, E. I., González‐Béjar, M., Gorelsky, S. I., Ebensperger, R., López‐Alarcón, C., Netto‐Ferreira, J. C., & Scaiano, J. C. (2010) · Photochemical & Photobiological Sciences · doi:10.1039/c0pp00102c · Cited by 13
Preventive effects of simvastatin nanoliposome on isoproterenol-induced cardiac remodeling in mice
Tuerdi, N., Xu, L., Zhu, B., Chen, C., Cao, Y., Wang, Y., Zhang, Q., Li, Z., & Qi, R. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.05.002 · Cited by 13
Modulation of heat shock proteins by statins
Forouzanfar, F., Butler, A. E., Banach, M., Barreto, G. E., & Sahbekar, A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.020 · Cited by 13
Development of predictive quantitative retention-activity relationship models of HMG-CoA reductase inhibitors by biopartitioning micellar chromatography
Wang, S., Chen, Y., Wu, L., Miao, W., Xiong, M., Chen, C., Zhong, Z., & Ye, L. (2007) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2007.09.024 · Cited by 13
Systemic evaluation of gene expression changes in major target organs induced by atorvastatin
Kato, N., Liang, Y.-Q., Ochiai, Y., & Jesmin, S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.043 · Cited by 13
Statins rise cytoplasmic calcium level [Ca2+]i in cultured endothelial cells.
Lorkowska, B., Chłopicki, S., Marcinkiewicz, E., & Gryglewski, R. J. (2004) · PubMed · Cited by 13
Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil
Hendriks, F., Kooman, J. P., & SANDE, F. M. V. D. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.12.2418 · Cited by 13
Aggressive Lipid Management for Cardiovascular Prevention: Evidence from Clinical Trials
Friday, K. E. (2003) · Experimental Biology and Medicine · doi:10.1177/15353702-0322807-01 · Cited by 13
Pharmacokinetics and Bioequivalence Study of Two Tablet Formulations of Lovastatin in Healthy Volunteers
Mignini, F., Tomassoni, D., Streccioni, V., Traini, E., & Amenta, F. (2008) · Clinical and Experimental Hypertension · doi:10.1080/10641960801944249 · Cited by 12
Simvastatin nanoliposome induces myocardial and hepatic toxicities due to its absorption enhancement in mice
Tuerdi, N., Anwaier, G., Zhang, X., Liu, S., Shen, W., Liu, W., Shen, Q., & Qi, R. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.02.002 · Cited by 12
Synergistic effect of hydrotrope and surfactant on solubility and dissolution of atorvastatin calcium: screening factorial design followed by ratio optimization.
Patel, V. F., & Sarai, J. (2014) · PubMed Central · Cited by 12
Perioperative Statin Use: An Update
Kalarickal, P. L., Fox, C. J., Tsai, J. Y., Liu, H., & Kaye, A. D. (2010) · Anesthesiology Clinics · doi:10.1016/j.anclin.2010.08.007 · Cited by 12
Pitavastatin and carbohydrate metabolism: what is the evidence?
Filippatos, T. D., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1165607 · Cited by 12
Effects of Bile Salts on Gastrointestinal Absorption of Pravastatin
Chun, I. K., Lee, K. M., Lee, K. E., & Gwak, H. S. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23123 · Cited by 12
Simvastatin, Sildenafil and Their Combination in Monocrotaline Induced Pulmonary Arterial Hypertension
Lee, D. S., Kim, Y. K., & Jung, Y. W. (2010) · Korean Circulation Journal · doi:10.4070/kcj.2010.40.12.659 · Cited by 12
Atorvastatin-Induced Hemorrhagic Cystitis: A Case Report
Martinez‐Suarez, H. J., Wang, R., & Faerber, G. J. (2008) · Urology · doi:10.1016/j.urology.2008.03.027 · Cited by 12
Lacidipine Modulates the Secretion of Matrix Metalloproteinase-9 by Human Macrophages
Bellosta, S., Canavesi, M., Favari, E., Cominacini, L., Gaviraghi, G., Fumagalli, R., Paoletti, R., & Bernini, F. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38810-x · Cited by 12
Self-citation
Statins for primary prevention of venous thromboembolism
Li, L., Sun, T., Zhang, P., Tian, J., & Yang, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008203.pub2 · Cited by 12
Apolipoprotein E deficiency potentiates macrophage against Staphylococcus aureus in mice with osteomyelitis via regulating cholesterol metabolism
Lu, M., He, R., Li, C., Liu, Z., Chen, Y., Yang, B., Zhang, X., & Yu, B. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1187543 · Cited by 11
HMG-CoA reductase inhibitor simvastatin ameliorates trimethyltin neurotoxicity and cognitive impairment through reversal of Alzheimer’s-associated markers
Salari, A., Roghani, M., & Khalili, M. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01515-4 · Cited by 11

Authors: Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F.
Affiliations: University of Milan (IT)
University of Parma (IT)
Corresponding author: Corsini, Alberto
ORCID: Corsini, Alberto
Bellosta, Stefano
Baetta, Roberta
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 1999-12
Volume: 84
Issue: 3
Pages: 413-428
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/s0163-7258(99)00045-5
OpenAlex: W2045063002
Cited by: 796
References: 186
Citations by year: 2026: 5 · 2025: 6 · 2024: 27 · 2023: 19 · 2022: 17 · 2021: 25 · 2020: 17 · 2019: 14 · 2018: 21 · 2017: 30 · 2016: 30 · 2015: 27 · 2014: 35 · 2013: 31 · 2012: 38
FWCI: 5.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: statins, pharmacokinetics, pharmacodynamics, HMG-CoA reductase inhibition, mevalonate, pleiotropy, smooth muscle cell proliferation, macrophage cholesterol accumulation, atherosclerosis, drug interactions, CYP3A4, cyclosporine, rhabdomyolysis, myositis, pravastatin, fluvastatin, simvastatin, lovastatin, atorvastatin, cerivastatin
MeSH terms: Atorvastatin, Fluvastatin, Animals, Anticholesteremic Agents, Cell Division, Cytochrome P-450 Enzyme System, Drug Interactions, Fatty Acids, Monounsaturated, Heptanoic Acids, Humans, Indoles, Mevalonic Acid, Pyridines, Pyrroles, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

New insights into the pharmacodynamic and pharmacokinetic properties of statins

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks